Publications in collaboration with researchers from Merck Institute for Science Education (1)

2023

  1. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial

    The Lancet Oncology, Vol. 24, Núm. 12, pp. 1399-1410